Free Trial
→ Trump doesn’t give a damn (From Porter & Company) (Ad)

Insulet Q2 2023 Earnings Report

Insulet logo
$282.80 -5.49 (-1.90%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Insulet EPS Results

Actual EPS
$0.38
Consensus EPS
$0.24
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Insulet Revenue Results

Actual Revenue
$396.50 million
Expected Revenue
$383.97 million
Beat/Miss
Beat by +$12.53 million
YoY Revenue Growth
N/A

Insulet Announcement Details

Quarter
Q2 2023
Date
8/8/2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Full Screen Slide Deck
Powered by Quartr

Insulet Earnings Headlines

Insulet: Aiding Patients And Investors
February 22 at 1:51 AM | seekingalpha.com
Insulet’s Financial Challenges: Navigating Pandemic Risks and Cybersecurity Threats
February 22 at 1:30 AM | tipranks.com
[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIED
Robert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy. Democrats smeared RFK Jr as a fraud, liar and even a murderer…. to stop him from revealing Big Pharma’s biggest secrets…
February 22, 2025 | NewMarket Health Publishing, LLC. (Ad)
Insulet price target raised to $293 from $245 at Stifel
February 22 at 12:17 AM | markets.businessinsider.com
Insulet price target raised to $325 from $317 at Morgan Stanley
February 21 at 7:16 PM | markets.businessinsider.com
Insulet (PODD) Receives a Hold from Stifel Nicolaus
February 21 at 7:16 PM | markets.businessinsider.com
See More Insulet Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Insulet? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insulet and other key companies, straight to your email.

About Insulet

Insulet (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

View Insulet Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles